医药生物行业周报：兴齐低浓度阿托品正式获批，关注近视防控蓝海市场

Investment Rating - The industry investment rating is "Maintain Accumulate" for the pharmaceutical and biotechnology sector [5]. Core Viewpoints - The approval of low-concentration atropine by Xingqi Eye Pharmaceutical is a significant positive development for the myopia prevention market, which is a blue ocean opportunity. The drug is aimed at children aged 6 to 12 years with myopia between 100 to 400 degrees and astigmatism not exceeding 150 degrees [3][11]. - The myopia rate among Chinese youth is alarmingly high, with a reported overall rate of 51.9% in 2022, affecting over 90 million children and adolescents. This has led to myopia prevention becoming a national strategy, with government initiatives aimed at reducing the prevalence of myopia [12][13]. Market Review - During the week of March 18-22, 2024, the A-share pharmaceutical and biotechnology sector fell by 2.13%, underperforming the CSI 300 index by 1.43 percentage points and the ChiNext index by 2.97 percentage points. The sector ranked 30th among 31 first-level sub-industries [2][13]. Company Dynamics - Recent announcements include the approval of clinical trial applications for various drugs by companies such as Betta Pharmaceuticals and Suzhou Micron Medical Technology, indicating ongoing innovation and regulatory progress within the industry [18].